CTGF is overexpressed in papillary thyroid carcinoma and promotes the growth of papillary thyroid cancer cells. (Q54377230)

29 May 2018

title

CTGF is overexpressed in papillary thyroid carcinoma and promotes the growth of papillary thyroid cancer cells. (English)

1 reference

29 May 2018

1 reference

papillary thyroid cancer

1 reference

Lei Cui

1

1 reference

29 May 2018

Qing Zhang

2

1 reference

29 May 2018

Zhengfa Mao

3

1 reference

29 May 2018

Jixiang Chen

4

1 reference

29 May 2018

Xuqing Wang

5

1 reference

29 May 2018

Jianguo Qu

6

1 reference

29 May 2018

Jianxin Zhang

7

1 reference

29 May 2018

Dayong Jin

8

1 reference

29 May 2018

publication date

20 April 2011

1 reference

29 May 2018

published in

Tumor Biology

1 reference

29 May 2018

volume

32

1 reference

29 May 2018

issue

4

1 reference

29 May 2018

page(s)

721-728

1 reference

29 May 2018

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

P53 mutations in thyroid carcinoma: tidings from an old foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Epidermal growth factor stimulates cell proliferation and inhibits iodide uptake of FRTL-5 cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

CCN family 2/connective tissue growth factor (CCN2/CTGF) regulates the expression of Vegf through Hif-1alpha expression in a chondrocytic cell line, HCS-2/8, under hypoxic condition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

The modular architecture of a new family of growth regulators related to connective tissue growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

CCN proteins: multifunctional signalling regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Expression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0173-6

Expression of connective tissue growth factor in cartilaginous tumors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21503841

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effects of type I-interferons on human thyroid epithelial cells derived from normal and tumour tissue

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21503841

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13277-011-0173-6

1 reference

29 May 2018

1 reference

29 May 2018